Company Overview
Altheia Science
- Industry: Biotechnology Research
- Company Size: 2-10 employees
- Locations:
- Italy: Via Conservatorio, 30, 20122 Milano
- US: The Empire State Building, 350 Fifth Avenue, Suite 7530, New York, NY 10118
- Mission: Committed to transforming patient lives through innovative and curative cell and gene therapies targeting autoimmune diseases and liquid tumors.
Key Products and Services
- Core Competencies: Specializes in stem cell-based therapeutics for cancer and autoimmune diseases, utilizing advanced cell and gene therapy strategies.
- Notable Products: Therapeutic solutions for autoimmune diseases.
Founders and Leadership
Co-Founders:
- Prof. Alessandra Biffi, MD: Co-Founder, Board Member & Chief Scientific Officer. Expertise in pediatric hematology and stem cell transplantation.
- Prof. Paolo Fiorina, MD, PhD: Co-Founder & Chief Scientific Officer. Renowned for contributions to endocrinology research.
- Paolo Rizzardi, MD: Co-Founder, Chairman of the Board & CEO, showcasing a blend of scientific and managerial expertise.
Key Personnel:
- Annita Montepeloso, PhD: Researcher Officer
- Rita Milazzo, PhD: Researcher Director
- Martina Pigazzi, PhD: Scientific Advisor
Board of Directors:
Includes influential members such as Gaurav Shah, MD, Gaudenzio Roveda, Raffaele Petrone, PharmD, and Enzo Adamo, JD.
Strategic Initiatives and Partnerships
- Collaborations: Engages with AGC Biologics to bolster its gene therapy initiatives.
- Innovations: Actively supports #GeneTherapy2point0 for enhancing Type 1 Diabetes clinical trials and advancing biotechnology in Italy.
Corporate Highlights
- Recognized for its innovative therapeutic pipeline and strategic market presence in the biotech startup sphere.
- Engaged with networks like Genenta Science to enhance its industry participation.
Competitor Profiling
Key Competitors
Altheia Science operates in a dynamic competitive landscape with several notable rivals:
- Neogene Therapeutics: Focuses on personalized T-cell therapies for cancer, recently incorporated into AstraZeneca, enhancing its research capabilities.
- Instil Bio: Develops innovative therapies, including AXN-2510 for solid tumors, backed by strong leadership and investment.
- Redbiotec AG: Based in Zurich-Schlieren, it collaborates with major pharma companies like Pfizer to create vaccines and genetic solutions.
- Empirica Therapeutics: Utilizes genomics platforms for adoptive immunotherapies, targeting aggressive cancers.
Industry Context and Strategic Position
- Funding: Approximately $11 million.
- Geographical Reach: Established presence in both Milan and New York, with Lombardia serving as a hub for pharmaceutical innovation.
- Competitive Environment: Competes with industry giants like Roche, Boehringer Ingelheim, Thermo Fisher Scientific, and Agilent Technologies.
Competitive Analysis
Altheia Science must leverage its biotechnology expertise amid fierce competition. Neogene's acquisition by AstraZeneca, Redbiotec's robust partnerships, and the cutting-edge cancer therapies by Instil Bio and Empirica highlight the competitive pressures. Strategic collaborations could enhance Altheia's therapeutic range and market impact, securing its positioning in biotechnology research and innovation.
